Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 258Radiotherapy 193Cetuximab 151pembrolizumab 123Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 78Radiotherapy, Intensity-Modulated 72Surveys and Questionnaires 46Nivolumab 42Drug Therapy 34Radiation 33Blood Specimen Collection 27Erlotinib Hydrochloride 26Gemcitabine 25Immunohistochemistry 22Gefitinib 22Cyclophosphamide 22Surgical Procedures, Operative 21Standard of Care 20durvalumab 19Pemetrexed 19Magnetic Resonance Spectroscopy 19Radiosurgery 17Capecitabine 17Chemotherapy, Adjuvant 16Celecoxib 16Biopsy 16atezolizumab 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Rosiglitazone × Head & Neck × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡